Publications by authors named "Stefan Halper"
Purpose: The Clinical Treatment Score post-5 years (CTS5) is an easy-to-use tool estimating the late distant recurrence (LDR) risk in patients with hormone receptor-positive breast cancer after 5 years of endocrine therapy (ET). Apart from evaluating the prognostic value and calibration accuracy of CTS5, the aim of this study is to clarify if this score is able to identify patients at higher risk for LDR who will benefit from extended ET.
Methods: Prognostic power, calibration, and predictive value of the CTS5 was tested in patients of the prospective ABCSG-06 and -06a trials (n = 1254 and 860 patients, respectively).
Article Synopsis
- The study aimed to validate the OncoMasTR Risk Score in predicting the risk of distant recurrence (DR) in postmenopausal women with specific breast cancer characteristics within the ABCSG Trial 8.
- It involved analyzing 1,200 tissue samples and found that 78.2% of the patients were classified as low risk, with significantly lower DR rates at 10 years for this group compared to those classified as high risk.
- The OncoMasTR Risk Score proved to be a strong prognostic tool, providing additional valuable information beyond traditional clinical assessments and reinforcing previous validation studies.